Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs are the recommended medication class for long-term prevention of panic attacks, with SNRIs as an alternative option. 1
Primary Recommendation
SSRIs represent the first-line pharmacologic treatment for panic disorder based on their:
- Strong efficacy in preventing panic attacks 2
- Superior long-term tolerability profile compared to other medication classes 3, 4
- Lack of dependence potential unlike benzodiazepines 5
- Effectiveness in treating anticipatory anxiety and avoidance behaviors that accompany panic attacks 6
The most robust evidence supports paroxetine and fluoxetine within the SSRI class, though sertraline also demonstrates efficacy 2. These medications require 12-24 months minimum of maintenance treatment, and some patients may need indefinite therapy given the chronic nature of panic disorder 3.
Alternative: SNRIs
SNRIs (particularly venlafaxine) can be offered as an alternative first-line option for panic disorder prevention 1. The evidence shows:
- High-quality data demonstrating improvement in clinician-reported anxiety symptoms 1
- Similar efficacy profile to SSRIs 7, 4
- Duloxetine has FDA approval for generalized anxiety disorder in children/adolescents, though the class is effective for panic disorder 1
Critical Implementation Points
Start with subtherapeutic "test" doses because SSRIs can paradoxically cause initial anxiety or agitation 1. Titrate slowly:
- Shorter half-life SSRIs (sertraline, citalopram): increase every 1-2 weeks
- Longer half-life SSRIs (fluoxetine): increase every 3-4 weeks 1
Monitor for treatment-emergent suicidal ideation, particularly in patients under age 24 1.
Why Not Benzodiazepines for Long-Term Prevention?
While benzodiazepines (alprazolam, clonazepam, diazepam) show rapid efficacy and rank highest for acute response and tolerability 2, they are explicitly not recommended for long-term prevention due to:
- Development of tolerance and physical dependence 6
- Cognitive impairment with chronic use 8
- Withdrawal syndromes 8
- Risk profile that makes them unsuitable beyond short-term adjunctive use 3, 9
Benzodiazepines may be used only as short-term adjuncts during the first days/weeks while waiting for antidepressant onset of action 6, but should not be the primary long-term prevention strategy.
Combination Treatment Consideration
For moderate-to-severe panic disorder, combining CBT with an SSRI provides superior outcomes compared to either treatment alone 1. The Child-Adolescent Anxiety Multimodal Study (CAMS) demonstrated that combination treatment with sertraline plus CBT achieved better response, remission, and global function than monotherapy 1.
Other Medication Classes
TCAs and MAOIs demonstrate efficacy but are not first-line due to:
- More problematic side effect profiles 5, 2
- Safety concerns in overdose (TCAs) 3
- Dietary restrictions and drug interactions (MAOIs) 1
These should be reserved for treatment-resistant cases 4, 9.
Anticonvulsants, antipsychotics, buspirone, and beta-blockers have limited evidence and should be considered third-line agents only 9.